Journal of Gastrointestinal Surgery

, Volume 16, Issue 9, pp 1639–1640 | Cite as

Introduction: Personalized Medicine in Gastrointestinal Cancer

SSAT State-of-the-Art Conference


Personalized medicine Translational research Genomics Proteomics 


  1. 1.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. Oct 11 2007;357(15):1555–1556; author reply 1556.PubMedCrossRefGoogle Scholar
  2. 2.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol. Dec 2004;11(12):1030–1034.PubMedCrossRefGoogle Scholar
  3. 3.
    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol. Dec 2002;9(10):941–943.PubMedGoogle Scholar
  4. 4.
    Barber M, Fitzgerald RC, Caldas C. Familial gastric cancer—aetiology and pathogenesis. Best Pract Res Clin Gastroenterol. 2006;20(4):721–734.PubMedCrossRefGoogle Scholar
  5. 5.
    Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol. Aug 2002;9(7):607–609.PubMedCrossRefGoogle Scholar
  6. 6.
    Mukherjee A, McGarrity TJ, Ruggiero F, et al. The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program. Hered Cancer Clin Pract. 2010;8:9.PubMedCrossRefGoogle Scholar
  7. 7.
    Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.PubMedCrossRefGoogle Scholar
  8. 8.
    Marrari A, Trent JC, George S. Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. Curr Opin Oncol. Jul 2010;22(4):336–341.PubMedCrossRefGoogle Scholar
  9. 9.
    Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2007(4):CD003805.Google Scholar
  10. 10.
    De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. Mar 2008;19(3):508–515.PubMedCrossRefGoogle Scholar
  11. 11.
    Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. Apr 23 2007;96(8):1166–1169.PubMedCrossRefGoogle Scholar
  12. 12.
    Hutchins G, Southward K, Handley K, et al. Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. J Clin Oncol. Mar 7 2011.Google Scholar
  13. 13.
    OncotypeDX. Accessed March 16, 2011.
  14. 14.
    Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. Apr 10 2009;27(11):1806–1813.PubMedCrossRefGoogle Scholar
  15. 15.
    Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. Apr 2008;15(4):956–960.PubMedCrossRefGoogle Scholar
  16. 16.
    Scartozzi M, Pistelli M, Bittoni A, et al. Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy. Curr Oncol Rep. May 2010;12(3):175–185.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2012

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations